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Italy 
1. Introduction 
Abbreviations and acronyms in this chapter. 
ENaC: amiloride-sensitive epithelial sodium channel; ROMK: renal outer medullary K 
channel; BK K+: flow-sensitive maxi K channel; AQP-2: apical aquaporin; AQP-3 and 4: 
basolateral aquaporin; 11β-HSD2: 11β-hydroxysteroid dehydrogenase; NAD: nicotinamide 
adenine dinucleotide; ROS: reactive oxygen species; CYP11B2: aldosterone synthase; GPR30: 
G protein coupled receptor; PI3K: phosphatidylinositol 3-kinase; ERK: extracellular signal-
regulated kinase; NYHA: New York Heart Association; HFPSF: heart failure and preserved 
systolic function (HFPSF); ACE: angiotensin-converting enzyme; CCB: calcium-channel 
blockers.  
Many clinical studies have reported that cardiovascular morbidity and mortality have a 
continuous relationship with both systolic and diastolic blood pressures. Although some of 
these studies have reported that this relationship is steeper for stroke, in some European 
countries the attributable risk, that is the excess of events due to increased blood pressure, 
appears to be greater for coronary artery disease (Prospective Studies Collaboration, 2002). 
Current evidence indicates that both systolic and diastolic blood pressure levels have a 
continuous and independent relationship with a variety of additional organ complications, 
including congestive heart failure, renal failure, and peripheral artery disease. The wide 
prevalence of hypertension in the general population (Wolf-Maier et al. 2003) explains why 
hypertension has been identified as the first cause of death worldwide by the World Health 
Organization. This is also why today hypertension is considered as the most important 
correctable risk factor for cardiovascular diseases. 
Recent guidelines have put strong emphasis on the relevance of hypertension-related 
subclinical organ damage and have prescribed that signs of organ involvement should be 
sought with great care. In fact, a large body of evidence indicates that hypertensive 
subclinical organ damage, including left ventricular hypertrophy, microalbuminuria, and 
thickening of inner vascular layers, is critical in determining the cardiovascular risk of 
individuals with high blood pressure (The Task Force for the Management of Arterial 
Hypertension of the European Society of Hypertension and of the European Society of 
Cardiology, 2007). In patients with high blood pressure, left ventricular hypertrophy has 
been shown repeatedly to be associated with an increased incidence of cardiovascular 
events, and similar evidence has been obtained for carotid intima-media thickening and 
microalbuminuria. Also and most important, prospective studies have demonstrated that 
reduction in left ventricular mass, intima-media thickness, and urinary protein excretion 
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induced by antihypertensive treatment are associated with reduced incidence of 
cardiovascular events. This indicates that assessment of subclinical organ damage is critical 
not only for quantification of the cardiovascular risk, but also to monitor the beneficial 
effects of treatment. Large clinical trials that have evaluated the effects of blockade of the 
renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers have demonstrated a specific ability of these agents in preventing 
progression and inducing regression of hypertension-related subclinical organ damage. It 
must be noticed, however, that a significant percentage of hypertensive patients with left 
ventricular hypertrophy fail to achieve full regression of left ventricular mass when treated 
with renin-angiotensin system blockers, a fact that might be ascribed to plasma aldosterone 
escape from the inhibitory effect of these drugs. This hypothesis received the support of 
studies in which it was demonstrated that with use of renin-angiotensin system blockers left 
ventricular mass does not decrease in hypertensive patients with aldosterone escape as 
opposed to a decline in left ventricular mass that is observed in patients without aldosterone 
escape. 
Several randomized controlled trials have tested the benefits of blood pressure lowering 
treatment providing undisputable evidence. Also, several meta-analyses that have collected 
an impressive number of patients have confirmed the evidence of benefits of treatment in 
event-based trials comparing active treatment with placebo, different active treatments, and 
more or less intense blood pressure lowering strategies. Findings of all these studies indicate 
that: a) use of antihypertensive drugs causes significant reductions of cardiovascular 
morbidity and mortality; b) reduction of cardiovascular risk is comparable in hypertensive 
patients of different ethnicity; c) the benefit of antihypertensive treatment is evident even in 
the elderly patients with isolated systolic hypertension; d) relative reduction of risk is 
greater for stroke (approximately 35%) than for coronary artery disease (approximately 
20%). Overall, studies comparing different types of antihypertensive drugs show that 
differences in the incidence of cardiovascular morbidity and mortality are not relevant in the 
presence of comparable blood pressure reduction, thus supporting the conclusion that 
benefits of treatment are largely dependent on blood pressure reduction per se.  
Diuretics decrease the total body pool of sodium-chloride and are included among the five 
major classes of antihypertensive agents that are suitable for the initiation and maintenance 
of antihypertensive treatment alone or in combination. This is due to the evidence of 
effective blood pressure lowering and effective prevention of cardiovascular events that has 
been obtained with thiazide diuretics. Current guidelines indicate congestive heart failure, 
isolated systolic hypertension, hypertension in blacks, and end-stage renal disease (this for 
loop diuretics) as conditions favoring use of diuretics versus other antihypertensive drugs. 
However, side effect of these drugs including decrease in plasma potassium, and increase in 
plasma glucose, cholesterol, triglyceride, and uric acid are important limiting factors. 
Other classes of diuretics that are used in hypertension as monotherapy, but more 
frequently as combinations, are the so-called potassium-sparing diuretics. These include a 
group of drugs that act with different mechanisms at the distal tubular site of the nephron 
where the mineralocorticoid receptors are expressed and mediate the tubular effects of 
aldosterone and other mineralocorticoid hormones. The aldosterone-sensitive tubular site of 
the distal tubule handles only a small amount of sodium chloride and this is why the 
natriuretic effect of agents acting at this site is relatively modest. However, this tubular site 
contributes greatly to regulation of body potassium content and acid-base equilibrium by 
modulation of exchange of sodium with either potassium or hydrogen ions.  
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Aldosterone is a steroid hormone that is secreted by the zona glomerulosa of the adrenal 
cortex and is involved in regulation of blood pressure exerting its main effects on the distal 
tubular site of the nephron where it increases water and sodium chloride reabsorption 
thereby leading to expansion of the extracellular fluid volume. Recent views indicate that, in 
addition to its renal effects and regulatory role on body water and electrolyte balance, 
aldosterone acts on a variety of cell types affecting cellular mechanisms that mediate 
important tissue responses, including hypertrophy and fibrosis. Recent evidence obtained 
from experimental animal studies indicates that chronic exposure to inappropriately high 
aldosterone levels or activation of the mineralocorticoid receptors can induce tissue damage 
in specific organ sites with mechanisms that are independent of blood pressure elevation. 
These animal studies have demonstrated that tissue damage can be prevented by removal of 
adrenal glands or administration of aldosterone antagonists. 
Spironolactone and eplerenone (Figure 1) are mineralocorticoid receptor antagonists 
commonly employed to reduce blood pressure, left ventricular hypertrophy, and urinary 
albumin excretion in patients with essential hypertension or primary aldosteronism. The 
latter effects occur beyond what is expected from the mere reduction of blood pressure, 
suggesting that activation of the mineralocorticoid receptor plays a central role in the 
development of cardiac and renal abnormalities in hypertensive patients. In agreement with 
 
 
 
Fig. 1. Structure of the mineralocorticoid receptor antagonists currently available for clinical 
use 
these findings, currently available evidence strongly supports the notion that aldosterone 
receptor antagonists are of considerable therapeutic value in patients with systolic heart 
failure with a cardioprotective effect that is already appreciable in the early functional 
Spironolactone 
Canrenone 
Eplerenone 
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stages. Also, recent evidence suggests that the benefits of aldosterone antagonists in the 
context of cardiac failure are not restricted to patients with impaired systolic function but 
can be extrapolated also to patients with diastolic dysfunction. Finally, some studies support 
the view that mineralocorticoid receptor blockade may exert an antialbuminuric effect in 
patients with proteinuria, an effect that occurs independent of blood pressure reduction.  
The use of classic mineralocorticoid receptor antagonists, however, has been limited by the 
high incidence of breast engorgement and gynecomastia and the risk of severe 
hyperkalemia. To overcome these tolerance problems, new aldosterone blockers have been 
developed (Garthwaite & McMahon 2004) using two different strategies that include search 
for non-steroidal antagonists and inhibition of aldosterone synthesis. Inhibition of 
aldosterone synthesis could have an additional benefit due to blockade of the 
mineralocorticoid receptor-independent pathways that might account for some of the 
untoward effects of aldosterone. The new aldosterone blockers are currently having 
extensive preclinical evaluation, and one of them has passed phase-II trials showing 
promising results in patients with essential hypertension and primary aldosteronism. 
2. Regulation of potassium excretion at the distal tubular site 
More than 98% of total body potassium is located inside the cells and homeostatic control of 
extracellular potassium by the intracellular pool is critical in the regulation of plasma 
potassium concentration. Plasma potassium levels are maintained stable between 3.5 and 5.0 
mEq/l despite remarkable variability in potassium intake with meals. This balance is due to 
mechanisms that operate principally at the renal level and regulate potassium excretion. In 
normal conditions, daily intake of potassium is entirely eliminated by the body, 90% by the 
kidney and 10% by the intestine.  Therefore, changes in body potassium content are 
physiologically regulated by the kidney that compensates with increased reabsorption in 
conditions of hypokalemia, and increased secretion in conditions of hyperkalemia. 
Potassium transport occurs along the entire nephron, but the major role in potassium 
secretion is played at the distal site by the connecting tubule and cortical collecting duct. In 
these sites, principal cells are responsible for regulation of sodium reabsorption and via the 
amiloride-sensitive epithelial sodium channel (ENaC) (Figure 2) with the associated potassium 
and hydrogen ion excretion. Sodium entry via ENaC generates an excess of negative charges 
in the tubular lumen that causes intracellular potassium to leave the cell through the renal 
outer medullary K channel (ROMK) and the flow-sensitive maxi-K potassium channel (BK K+) 
(Figure 2). In addition to distal sodium reabsorption through the ENaC, potassium secretion is 
therefore dependent on distal tubular flow. Aldosterone has direct influence on potassium 
secretion, activating sodium transport through activation of the ENaC and increasing the 
driving force for potassium secretion into the tubular lumen (Figure 3). 
3. Mechanisms of aldosterone-induced tissue damage 
A growing body of evidence suggests that exposure to inappropriate aldosterone levels for 
salt status or activation of the mineralocorticoid receptor can produce massive myocardial, 
vascular, and renal tissue injury with mechanisms that are independent of blood pressure 
(Marney & Brown, 2007). Landmark experiments demonstrated that chronic aldosterone 
infusion causes myocardial fibrosis in rats that are maintained on a high-salt diet. Later on, 
it was demonstrated that aldosterone-induced myocardial fibrosis is preceded by 
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inflammatory changes of perivascular tissue, and that both inflammation and fibrosis can be 
prevented by administration of mineralocorticoid receptor antagonists or adrenalectomy. 
Similar evidence was obtained in the kidney of uninephrectomized and stroke-prone 
spontaneously hypertensive rats in which aldosterone produced intrarenal vascular 
damage, glomerular injury, and tubulointerstitial fibrosis. Elevated aldosterone also caused 
aortic fibrosis and hypertrophy in different rat models of hypertension, and administration 
of eplerenone to hypertensive rats corrected vascular remodeling and fibrosis, suggesting a 
mineralocorticoid receptor-mediated mechanism.  
 
Fig. 2. Sodium, potassium, and water transport in principal cells of connecting tubule and 
cortical collecting duct. ENaC: amiloride-sensitive epithelial sodium channel; ROMK: renal 
outer medullary K channel; BK K+: flow-sensitive maxi K channel; AQP-2: apical aquaporin; 
AQP-3 and 4: basolateral aquaporin. 
All these studies consistently indicate that aldosterone causes tissue damage only in the 
context of inappropriate salt status. It was suggested that untoward effects of high-salt 
intake are largely dependent on activation of mineralocorticoid receptors and that this 
activation might reflect increased oxidative stress. Mineralocorticoid receptors are found in 
epithelial and nonepithelial tissues with high affinity for aldosterone and glucocorticoid 
hormones, such as cortisol and corticosterone. Under physiological conditions, the majority 
of mineralocorticoid receptors in nonepithelial tissues are occupied by greater 
concentrations of cortisol, whereas in epithelial tissues, binding of cortisol to receptors is 
prevented by 11β-hydroxysteroid dehydrogenase (11β-HSD2), the enzyme that converts 
cortisol to the receptor-inactive cortisone. In addition to the conversion of cortisol to 
cortisone, activity of 11β-HSD2 generates NADH from NAD and produces changes in the 
intracellular redox potential that might, in turn, inactivate the glucocorticoid–receptor 
complex. 11β-HSD2 is not present in nonepithelial tissues including the heart, but in such 
tissues, changes of the intracellular redox potential can result from generation of reactive 
oxygen species (ROS) and thereby affect the activity of the mineralocorticoid receptor. 
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Fig. 3. Aldosterone (A) and cortisol (C) synthesis in the adrenal cortex and mechanisms of 
aldosterone action in the principal cells of the collecting duct. Aldosterone and cortisol 
originate from the metabolic conversion of cholesterol in the adrenal cortex. Finals steps of 
this conversion involve the cytochrome P450 enzymes CYP11B2 and CYP11B1 for the 
synthesis of aldosterone and cortisol, respectively. Aldosterone synthase inhibitors 
selectively block CYP11B2 and reduce aldosterone levels. In tubular cells, aldosterone 
activates the mineralocorticoid receptor and thereby induces structural and regulatory 
proteins that increase the activity of the epithelial sodium channel (ENaC), the renal outer 
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medullary potassium channel (ROMK), and the sodium/potassium ATPase pump. The net 
effect is sodium reabsorption in the bloodstream and potassium excretion in urine. Steroidal 
or non-steroidal mineralocorticoid receptor antagonists block the mineralocorticoid receptor 
activation by aldosterone. Inappropriate activation of mineralocorticoid receptors by cortisol 
is inhibited by its conversion to the receptor-inactive cortisone by the 11β-hydroxysteroid 
dehydrogenase (11βHSD2). 
In vitro experiments have demonstrated that changes in the redox potential of 
cardiomyocytes by exposure to oxidized glutathione turn cortisol from being a receptor 
antagonist to an agonist. More recently, it has been demonstrated that aldosterone itself 
induces changes in the intracellular redox potential in diverse cell types through an 
activation of the NOX1 catalytic subunit of NAD(P)H oxidase. This aldosterone-dependent 
change in the redox potential is amplified by exposure to high concentrations of salt leading 
to increased production of ROS and thereby to cellular and tissue injury.  
In fact, ROS are responsible for apoptosis of cardiomyocytes and for mesangial cell 
proliferation and matrix expansion in glomeruli of rats. In vascular tissues a slight increase 
in sodium concentration in the presence of aldosterone affects the biomechanical properties 
of the endothelial cells leading to cell swelling and cell stiffening (Figure 4). Both these 
effects are blunted by amiloride (a selective ENaC inhibitor) or spironolactone 
demonstrating the involvement of a mineralocorticoid receptor-dependent activation of 
ENaC pathway also in the vascular tissue (Figure 4). Furthermore, the analysis of gene 
expression profiling of vascular tissues demonstrated that, in the context of an enhanced 
oxidative stress, aldosterone can stimulate the expression of several pro-atherogenic genes 
and this expression can be inhibited by mineralocorticoid receptor antagonists. 
Thus, in addition to the well-known effects of salt loading on epithelial swelling, vascular 
stiffening and blood pressure increase, some effects of salt loading might depend on 
mineralocorticoid receptor activation and reflect, in different tissues, impairment of 11β-
HSD2 activity and/or increased oxidative stress, both mechanisms possibly leading to 
changes in the intracellular redox state. The distinction of these effects of salt from those 
generated at the tissue level by elevated aldosterone is complex and even genetic 
manipulations could not help in the understanding of their respective roles. In fact, both 
cardiac overexpression of the mineralocorticoid receptor and cardiac-specific induction of 
aldosterone production do not cause cardiac fibrosis, whereas fibrosis results from 
knockdown of the cardiac receptor by the use of antisense mRNA. 
Although the use of mineralocorticoid receptor antagonists can inhibit or reduce aldosterone 
effects, several rapid actions of aldosterone on vascular tissue, such as regulation of vascular 
tone are, at least in part, independent of mineralocorticoid receptor blockade. Therefore, a 
mineralocorticoid receptor-independent pathway and the existence of a new aldosterone 
receptor have been hypothesized (Figure 4). Recently, it has been shown that in vascular 
smooth muscle aldosterone action is linked to a mineralocorticoid receptor-independent 
pathway that is mediated by the G protein coupled receptor (GPR30) (Figure 4). This 
pathway involves phosphatidylinositol 3-kinase (PI3K) and the extracellular signal-
regulated kinase (ERK). These findings rise new questions on the role of aldosterone-related 
and mineralocorticoid receptor-independent pathways in causing tissue injury. 
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Fig. 4. Effect of aldosterone (A) on blood vessels. Aldosterone binds to mineralocorticoid 
receptors (MR) increasing generation of reactive oxygen species (ROS) and induces endothelial 
cell swelling and stiffening via a mineralocorticoid receptor-dependent pathway involving the 
NADPH oxidase and epithelial sodium channel, respectively. Both effects are blocked by 
mineralocorticoid receptor antagonists. Increased oxidative stress turns cortisol (C) to be an 
agonist rather than an antagonist of mineralocorticoid receptor. Aldosterone might exert its 
deleterious cardiovascular effects also through a mineralocorticoid receptor-independent 
pathway involving the G protein coupled receptor (GPR30) that can induce vascular smooth 
muscle cell apoptosis and inappropriate vasoconstriction. The pathophysiological role of these 
“non-genomic” effects of aldosterone needs to be further explored. 
4. Spironolactone 
Spironolactone (Figure 1) was synthesized in the Searle Laboratories in 1958 and its 
aldosterone blocking activity was discovered in 1959 (Cella et al., 1959). The molecule was 
approved for clinical use in 1962 and has been used for many decades in the treatment of 
primary aldosteronism, ascites associated with portal hypertension, and congestive heart 
failure. It has been used also for the treatment of primary hypertension (De Gasparo et al., 
1987). 
4.1 Metabolism 
Spironolactone is a well-absorbed (approximately 65%), lipid-soluble, and highly protein 
bound steroidal aldosterone antagonist. It is largely metabolized in a hepatic first-pass with 
a high degree of enterohepatic cycling and a half-life of 1.6 hours, as such. In fact, 
spironolactone is transformed to either 7-thiomethylspirolactone or canrenone, two active 
metabolites that account for much of its pharmacological activity. Canrenone has a 20-hour 
half-life, but this is prolonged in patients with cardiac insufficiency. Spironolactone is also 
an inducer of microsomal drug metabolizing enzymes in the liver. The onset of action of 
spironolactone is slow, with a peak response that is reached approximately 48 hours after 
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the first oral dose. Spironolactone is moderately more potent than eplerenone in blocking 
mineralocorticoid receptors. Spironolactone remains active when renal function is impaired 
because it reaches its site of action independent of glomerular filtration. This accounts for 
the risk of hyperkalemia observed in patients with chronic kidney disease and in patients 
with congestive heart failure and impaired renal function. 
4.2 Dosing 
The recommended oral dosing range of spironolactone is from 12.5 to 250 mg once or twice 
a day in primary hypertension and other disease conditions in which the use of this agent is 
indicated. 
4.3 Clinical use 
Spironolactone is a medication that has been used for more than 50 years to treat 
hypertension, edema, primary aldosteronism, and, more recent evidence indicates benefits 
also in patients with congestive heart failure and proteinuria. 
Almost a decade ago, a landmark trial investigated the effects of spironolactone in patients 
with functional class III-IV systolic heart failure, showing a significant decrease in the 
mortality rate as compared to patients who received placebo on top of conventional 
treatment. The Randomized Aldactone Evaluation Study (RALES) (Pitt et al., 1999) was 
conducted in patients with New York Heart Association (NYHA) class III-IV heart failure 
who were treated with spironolactone. More recently, it has been suggested that the benefits 
of spironolactone in the context of cardiac failure are not restricted to patients with impaired 
systolic function and some studies have tested the effects of spironolactone in patients with 
heart failure and preserved systolic function (HFPSF). Edwards et al. reported improved 
diastolic function parameters with use of spironolactone in 112 patients with stage 2-3 
chronic renal failure and HFPSF who were included in the Chronic Renal Impairment in 
Birmingham (CRIB II) study. In this study, the effects of spironolactone on left ventricular 
function and circulating markers of collagen turnover were compared with those of placebo. 
After 40 weeks, spironolactone improved significantly markers of left ventricular relaxation 
and attenuated significantly the increase in aminoterminal propeptide of type-III 
procollagen that was observed with placebo. This and other studies on HFPSF suggest a 
possible benefit of spironolactone also on this subtype of cardiac insufficiency. Notably, all 
these studies have employed doses of spironolactone (from 25 to 50 mg/day) that did not 
lower blood pressure suggesting that the cardioprotective effects of spironolactone occurs 
independent of the blood pressure-related hemodynamic load to the heart. Taken together, 
the findings obtained in the studies that have tested the effects of spironolactone in heart 
failure provide indirect evidence of untoward effect of aldosterone on the heart. 
Many studies have reported a beneficial effect of blockers of the renin-angiotensin-
aldosterone system in slowing down progression of renal disease, but the relative 
contributions of angiotensin II versus aldosterone have been dissociated only recently in 
animal studies. Clinical studies have supported the view that mineralocorticoid receptor 
blockade may exert an antialbuminuric effect in patients with proteinuria. In patients with 
diabetic nephropathy, it was shown that the antiproteinuric effect of angiotensin-converting 
enzyme (ACE) inhibitors reverts to baseline in patients who manifest aldosterone escape 
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and that spironolactone combined with an ACE inhibitor results in an additional decrease in 
albuminuria (Sato et al., 2003). Also, spironolactone effectively reduced proteinuria in 
patients with idiopathic chronic glomerulonephritis previously treated with either ACE 
inhibitors or angiotensin receptor blockers (Bianchi et al., 2005). Another, more recent, study 
has shown that spironolactone added to an ACE inhibitor or an angiotensin receptor blocker 
reduces albuminuria in patients with type 2 diabetes and nephropathy. Collectively, these 
observations suggest that the mechanisms of the antialbuminuric effect of spironolactone 
are independent of blood pressure reduction and occur on top of those of other blockers of 
the renin-angiotensin system.  
4.3.1 Essential hypertension 
The anti-hypertensive effects of spironolactone have been overviewed in a recent meta-
analysis that has included five cross-over studies and one randomized controlled trial with a 
total of 179 essential hypertensive patients that were followed from 4 to 8 weeks (Batterink 
et al., 2010). This meta-analysis showed that spironolactone decreases systolic and diastolic 
blood pressure by 20 and 7 mmHg, respectively, but this effect is reached with doses 
between 100 and 500 mg per day. With these doses, the risk of hyperkalemia is an important 
limitation and this is why use of spironolactone in the treatment of essential hypertension 
has been limited to combination with other types of diuretics. The dose of 25 mg/day did 
not change either systolic or diastolic blood pressure. None of the studies that were included 
in this meta-analysis reported results for hard endpoints such as mortality and major 
cardiovascular events. Therefore, at present there is no evidence that use of spironolactone 
decreases the risk of cardiovascular disease. 
Despite the effects of spironolactone on blood pressure in essential hypertensive patients are 
modest and there is no demonstration that spironolactone protects from cardiovascular 
events, possible benefits on subclinical hypertensive organ damage that might be obtained 
even with the lower doses of the drug should be considered. Some small studies conducted 
in patients with hypertension-induced left ventricular hypertrophy have reported that 
addition of spironolactone to blockers of the renin-angiotensin system increases the effects 
on left ventricular mass reduction. The effects of an ACE-inhibitor alone or an ACE-inhibitor 
plus spironolactone (25 mg/day) on blood pressure and left ventricular mass changes were 
compared in essential hypertensive patients with left ventricular hypertrophy. Left 
ventricular mass index decreased in both treatment groups, but the extent of reduction was 
significantly greater in patients who were treated with the combination of the ACE-inhibitor 
and spironolactone. Similarly, the effects of candesartan (8 mg/day) alone or combined with 
spironolactone (25 mg/day) were tested in patients with hypertension and different patterns 
of left ventricular geometry. Changes in blood pressure did not differ between the two 
groups, whereas only the combination of candesartan and spironolactone decreased left 
ventricular mass with a change that was significant only in patients with concentric 
hypertrophy. In another study, 30 hypertensive patients with impaired diastolic function were 
randomized to receive either 25 mg/day of spironolactone or placebo for 6 months. Peak 
systolic strain and cyclic variation of integrated backscatter were improved by spironolactone 
with significant differences with patients treated with placebo. Thus, current evidence 
indicates that spironolactone could have a considerable place in the treatment of essential 
hypertensive patients with left ventricular hypertrophy and/or diastolic dysfunction. 
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4.3.2 Resistant hypertension 
Several clinical case reports suggested that spironolactone can be useful in the treatment of 
resistant hypertension and, in particular, in hypertension associated to obesity or 
obstructive sleep apnea syndrome. One controlled and several non-controlled studies have 
confirmed that addition of 25-50 mg of spironolactone to current treatment effectively 
reduces blood pressure in patients with resistant hypertension. In the ASPIRANT trial, 117 
patients with resistant hypertension were randomized to treatment with spironolactone or 
placebo in a double-blind protocol. The trial was prematurely stopped after the first interim 
analysis because of a significant reduction of systolic blood pressure in patients taking 
spironolactone as compared to those taking placebo. Notably, the average BMI of the study 
population in this trial was 32.3 clearly indicating that patients were either obese or 
overweight. In the prospective, uncontrolled study of Souza et al., 175 patients with resistant 
hypertension were treated with 25-100 mg/day of spironolactone and, after a median 
interval of 7 months, 24-hour systolic and diastolic blood pressure decreased by 16 mm Hg 
and 9 mm Hg, respectively. The baseline characteristics of these patients showed again that 
they were either overweight or obese and had high prevalence of diabetes, dyslipidemia, left 
ventricular hypertrophy, and previous cardiovascular diseases. In the ASCOT-BPLA trial, 
patients who took spironolactone as fourth line therapy because of resistant hypertension 
were analyzed retrospectively. In these patients, spironolactone at a median dose of 25 
mg/day significantly reduced blood pressure by 21.9/9.5 mm. Even in this study, patients 
with resistant hypertension had significantly higher body mass index, systolic blood 
pressure, and prevalence of diabetes and left ventricular hypertrophy than patients who 
were not resistant to treatment. Very similar results were reported in other studies 
conducted on patients of different geographical areas. 
The beneficial effect of spironolactone in patients with resistant hypertension is currently 
unexplained, although this effect suggests a substantial contribution of aldosterone to 
maintenance of increased blood pressure despite of treatment. Inappropriate secretion of 
aldosterone has been reported in hypertensive patients with associated obesity and/or 
obstructive sleep apnea syndrome. Also, it is well known that aldosterone can escape the 
inhibitory effects of renin-angiotensin system blockers in patients treated with these drugs, 
thereby leading to a form of hypertension that is largely aldosterone-dependent. Finally, it 
cannot be excluded that, at least in some cases, resistance to antihypertensive treatment 
hides a mild form of primary aldosteronism. 
4.3.3 Primary aldosteronism 
Spironolactone is the drug of choice in the medical treatment of primary aldosteronism in 
which hypertension is due to an excessive aldosterone secretion from the adrenal gland. In 
this clinical setting, spironolactone reduces blood pressure, corrects hypokalemia, and 
reverts cardiac and renal abnormalities as it has been reviewed recently. This was 
demonstrated in long-term follow-up studies in which treatment with spironolactone 
reduced cardiovascular and renal events and decreased left ventricular mass and urinary 
protein excretion in patients with primary aldosteronism (Sechi et al., 2010).  
Cardiovascular outcomes were compared in 108 patients with essential hypertension and in 
54 patients with primary aldosteronism who were comparable for demographic variables 
and had comparable risk factors, but greater retrospective incidence of coronary artery 
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disease, cerebrovascular events, and sustained arrhythmias (Catena et al. 2008). Patients 
were followed for an average of 7.4 years after surgical removal of an adrenal adenoma or 
treatment with spironolactone, with a combined end point including myocardial infarction, 
stroke, any type of revascularization procedure, and sustained arrhythmias. During follow-
up, blood pressure was comparable in the primary aldosteronism and essential hypertension 
group, and 10 patients in the former group and 19 in the latter group reached the end point. 
Actuarial analysis of patients treated with surgery vs. spironolactone did not reveal significant 
difference in the occurrence of the combined end point. In the same cohort of patients, the 
outcomes of renal function were investigated by measuring the rates of change of glomerular 
filtration and albuminuria (Sechi et al., 2006). After an initial decline in creatinine clearance, 
due to correction of the aldosterone-induced intrarenal hemodynamic adaptation, subsequent 
decrease of glomerular filtration in patients with primary aldosteronism and essential 
hypertension were comparable. Urinary albumin losses did not differ between patients with 
primary aldosteronism and essential hypertension during follow-up. Evaluation of renal 
outcomes in patients with primary aldosteronism who were treated with surgery or 
spironolactone did not reveal significant difference. These two studies clearly demonstrate that 
spironolactone has the same therapeutic value as surgery in the treatment of primary 
aldosteronism and in the prevention of cardiovascular and renal complications. 
In addition to excess cardiovascular and renal events as compared to matched patients with 
essential hypertension, patients with primary aldosteronism are characterized by cardiac, 
renal, and metabolic subclinical structural and functional abnormalities (Rossi et al., 2008). A 
number of cross-sectional cardiac ultrasound studies have reported an excess increase of left 
ventricular mass in patients with primary aldosteronism as compared to other types of 
hypertensive disease. In a 7-year echocardiographic study it was demonstrated that patients 
with primary aldosteronism treated with either surgery or spironolactone have significant and 
comparable decrease of left ventricular mass, although decrease is significant within the first 
year only after adrenalectomy (Catena et al., 2007). We have already mentioned the effects of 
spironolactone on correction of albuminuria. These effects are at least in part related to reversal 
of an intrarenal hemodynamic adaptation to aldosterone excess with a vasodilatory response 
that has been demonstrated with intrarenal echo-Doppler examination (Sechi et al., 2009). 
5. Canrenoate 
Canrenone (Figure 1) is one of the two metabolites of spironolactone. It is administered 
orally as a potassium salt (potassium canrenoate) that is mineralocorticoid receptor-inactive, 
but it is rapidly transformed to canrenone. Canrenone is water soluble, and this 
characteristic permits intravenous administration when a rapid effect is desired.  
Potassium canrenoate exerts its hypotensive effect approximately one week after the starting 
dose. Both canrenone and canrenoate are rapidly absorbed (approximately 80%) after oral 
administration. Both agents have important plasma protein binding (approximately 90%) 
with small volumes of distribution.  
6. Eplerenone 
Eplerenone (Figure 1) has been synthesized in the attempt to obtain a more selective 
inhibition of the mineralocorticoid receptors to overcome the side effects due to cross-
reaction of spironolactone and canrenone with androgen receptors. It was synthesized in the 
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Ciba-Geigy laboratories in the mid-80s and was approved in the United States for clinical 
use in arterial hypertension in 2002.  
6.1 Pharmacology 
Eplerenone was synthesized by replacing the 17-thioacetyl group with a carbomethoxy 
group in the molecule of spironolactone (Figure 1). The critical feature in the eplerenone 
molecule however, conferring enhanced mineralocorticoid receptor selectivity is the presence 
of the epoxide group in the lactone ring. The activity of eplerenone in vitro was assessed in 
vitro using recombinant steroid receptors. The potency of eplerenone at other steroid receptors 
was significantly reduced and, unlike previous aldosterone blockers, eplerenone possesses 
very low activity on the androgen, progesterone, and glucocorticoid receptors.  
Oral bioavailability is approximately 95% and meals have no effect on the extent of 
absorption. Eplerenone does not undergo relevant metabolic first-pass in the liver neither it 
induces cytochrome P450 activity, although interactions with drugs that are metabolized by 
cytochrome P450 are not excluded. The two main metabolites of eplerenone (6β-OH 
eplerenone and open lactone ring) are both mineralocorticoid receptor-inactive. The plasma 
half-life of eplerenone is approximately 5 hours.  
The recommended oral dosing range for eplerenone is from 50 to 100 mg once or twice daily 
in essential hypertension. No correlations between eplerenone disposal and renal function 
have been found. 
6.2 Clinical use 
Eplerenone has come into the clinical arena in the last decade and has been employed to lower 
blood pressure in essential hypertensive patients. Similar to spironolactone, recent studies 
have reported beneficial effects of eplerenone in congestive heart failure and renal disease with 
proteinuria. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and 
Survival Study (EPHESUS) (Pitt et al. 2003) investigated the effects of eplerenone in post-
myocardial infarction patients with severely impaired left ventricular function, showing a 
significant decrease in the mortality rate as compared to patients who received placebo on top 
of conventional treatment. Recently, these observations have been extended to patients with 
milder degrees of cardiac dysfunction in the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF) (Zannad et al., 2011) study. In this study, 
2737 patients with NYHA class II cardiac insufficiency and left ventricular ejection fraction of 
less than 35% were randomized to receive either eplerenone or placebo in addition to 
conventional treatment. This trial ended prematurely after a median follow-up of 21 months 
because the composite endpoint of cardiovascular death and hospitalization for heart failure 
were significantly less frequent in patients who were treated with eplerenone. Thus, 
eplerenone seems to be beneficial even at the early stages of systolic cardiac failure. 
As for spironolactone, the possibility that eplerenone may result beneficial also in patients 
with HFPSF has been investigated. Forty-four elderly patients with heart failure and left 
ventricular ejection fraction of more than 45% were randomized to conventional treatment 
with or without eplerenone and left ventricular function was reassessed with conventional 
echocardiography and tissue Doppler imaging at 6 and 12 months. In patients who were 
treated with eplerenone, deceleration time had a significantly greater decrease than in 
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patients on conventional treatment and, after 12 months, the eplerenone-induced 
improvement of diastolic function was associated with a significantly slower increase in 
plasma procollagen levels. Both studies on systolic and diastolic heart failure were conducted 
with doses of eplerenone (from 25 to 50 mg/day) that did not lower blood pressure. 
Consistent with previous findings using spironolactone, eplerenone has been demonstrated 
to confer renal protection independent of its effects on blood pressure. Eplerenone was 
administered in doses of 50 and 100 mg/day to patients with type 2 diabetes and 
albuminuria who were already treated with an ACE inhibitor. After 4, 8, and 12 weeks, both 
doses of eplerenone induced significant reduction of urinary protein losses as compared to 
placebo, whereas blood pressure levels did not differ during follow-up. Effects of the two 
doses of eplerenone were comparable (Epstein, 2003). 
6.2.1 Essential hypertension 
Eplerenone has been repeatedly tested in patients with mild to moderate essential 
hypertension. One uncontrolled open-label study and many randomized controlled trials 
have documented the antihypertensive effect of eplerenone when compared to either 
placebo or other classes of antihypertensive agents. Controlled studies have compared the 
blood pressure lowering effects of eplerenone at doses comprised form 50 to 400 mg/day 
with those of either placebo, enalapril, losartan, amlodipine, or spironolactone. In these 
studies, follow-up duration was from 2 to 14 months. In all studies, eplerenone was more 
effective than placebo in reducing blood pressure, in two studies it was more potent than 
losartan, and in the remaining studies the hypotensive effects were comparable to those of 
enalapril, amlodipine, and spironolactone. Similar to spironolactone, none of these studies 
reported results for hard cardiovascular endpoints including mortality and major 
cardiovascular events and therefore there is no evidence that eplerenone improves 
cardiovascular outcomes in hypertensive patients. 
Eplerenone has been demonstrated to be beneficial also on hypertension-related subclinical 
organ damage. In the 4-E Left Ventricular Hypertrophy Study, regression of left ventricular 
hypertrophy was compared in essential hypertensive patients who were treated with 
eplerenone, enalapril, or their combination for 9 months. Left ventricular mass index 
decreased significantly and comparably in patients treated with eplerenone or enalapril, 
whereas the combination of the two agents showed additive effects on left ventricular mass 
reduction. In other studies, eplerenone was reported to be more effective than amlodipine, 
enalapril, or losartan in decreasing urinary albumin excretion.  
Despite eplerenone has a satisfactory tolerability and safety profile even at the highest doses 
that have been clinically tested (200 mg/day), its effects on blood pressure in essential 
hypertension and primary aldosteronism are inferior to those of spironolactone.  
7. Epithelial sodium channel blockers 
ENaC blockers are potassium-sparing compounds with weak diuretic properties. Both 
amiloride and triamterene are treatment of choice in the Liddle syndrome, but are relatively 
uneffective in essential hypertension when used as monotherapy and can be useful when 
used in combination with other types of diuretics that cause hypokalemia such as thiazides 
and loop diuretics.  
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No studies have evaluated the effects of ENaC blockers in monotherapy in patients with 
essential hypertension. Four studies with amiloride and 2 studies with triamterene have 
evaluated the dose-related blood pressure efficacy of these drugs when added, as a second 
antihypertensive agent, to hydrochlorothiazide or chlorthalidone (Heran et al., 2010).  
7.1 Amiloride 
Amiloride is a selective blocker of the ENaC. It is actively secreted by cationic carriers in the 
proximal tubule, reaching its active site at the distal tubule. At this level, amiloride 
indirectly antagonizes the effects of aldosterone on sodium-potassium exchange leading to 
increased sodium excretion with relative potassium retention. Amiloride is cleared by the 
kidney and can accumulate in patients with impaired renal function. Therefore, the dosage 
should be reduced when the glomerular filtration rate is below 50 ml/min.  
No studies have evaluated amiloride as monotherapy in patients with essential 
hypertension. Amiloride is administered in patients with essential hypertension usually in 
combination with thiazide diuretics. Amiloride can also be used in patients with primary 
aldosteronism when spironolactone is not tolerated. Although studies that have tested 
amiloride as an antihypertensive agents have reported good tolerability, particular caution 
is required in patients with renal failure or in patients treated with blockers of the renin-
angiotensin system because of the risk of hyperkalemia. 
Data on use of amiloride (from 2.5 to 5 mg/day) in combination with hydrochlorothiazide 
are insufficient to demonstrate a significant difference between treatment with the 
combination and hydrochlorothiazide alone. Therefore current evidence does not support 
any effect of low doses of amiloride on blood pressure. No trials evaluating doses of 
amiloride higher than 5 mg/day have been performed and therefore a dose-response 
relationship with the hypotensive effect can not be demonstrated. No effects of amiloride on 
pulse pressure or blood pressure variability could be demonstrated in the studies that have 
employed this agent in the treatment of hypertension. 
There are no appropriately designed studies that have tested the effects of amiloride in other 
disease conditions. In primary aldosteronism experiences are mainly anedoctal and the 
doses of this drug to use in this context have never been defined with precision. No studies 
have been performed to test the effects of amiloride on subclinical hypertensive organ 
damage, heart failure, and proteinuria. 
7.2 Triamterene 
Similar to amiloride, triamterene blocks the ENaC in the distal tubular site of the nephron. 
Triamterene is incompletely absorbed and is transformed to a sulphate-conjugated 
metabolite. It gains access to the tubular lumen via a cationic transporter in the proximal 
tubule. Both triamterene and its metabolite accumulate in patients with renal failure. When 
used alone, triamterene has little effect on blood pressure. Therefore it is usually employed 
in combination to compensate for the hypokalemic effects of other diuretics.  
No studies have evaluated triamterene as monotherapy in patients with essential 
hypertension. Data on use of triamterene (50 mg/day) in combination with chlorthalidone 
are insufficient to demonstrate a significant difference between treatment with the 
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combination and chlorthalidone alone. Therefore current evidence does not support any 
effect of low doses of triamterene on blood pressure. No data are currently available on the 
effects on blood pressure of higher doses of triamterene and therefore a dose-response 
relationship with the hypotensive effect can not be demonstrated. No effects of triamterene 
on pulse pressure or blood pressure variability could be demonstrated in the studies that 
have employed this agent in the treatment of hypertension. Tolerability and safety profile of 
triamterene in the studies that have tested this drug were acceptable. 
There are no studies that have tested the effects of triamterene in other disease conditions. In 
primary aldosteronism experiences are mainly anedoctal and the doses of this drug that 
should be used in this endocrine disorder have never been specifically defined. No studies 
have been conducted to investigate the effects of triamterene on subclinical hypertensive 
organ damage, heart failure, and proteinuria. 
8. New aldosterone blockers 
Promising results with mineralocorticoid receptor antagonists in the treatment of 
hypertension and prevention of hypertension-related organ damage have prompted the 
search and possible development of new aldosterone antagonists. Search has followed two 
main strategies: the first has consisted in the development of non-steroidal antagonists that 
could overcome the side effects of spironolactone and canrenoate without losing the 
pharmacological properties of these compounds; the second has aimed at developing drugs 
that inhibit aldosterone biosynthesis and has resulted in the generation of aldosterone 
synthase direct inhibitors.  
8.1 Non steroidal mineralocorticoid receptor antagonists 
The first strategy moved its initial steps from the demonstration that some dyhydropyridine 
calcium-channel blockers (CCBs) exerts also a mineralocorticoid receptor antagonist activity. 
Researchers in the Pfizer® laboratories reported that nimodipine, felodipine, and 
nitrendipine block aldosterone-induced receptor activation by competing with aldosterone 
binding to the receptor “ligand binding domain”. The affinity of dihydropyridines for the 
receptor binding domain is lower than for the L-type calcium channels, indicating that 
inhibition of mineralocorticoid receptor activity is independent of the effects on calcium 
channels. The efficacy of dyihydropyridines as mineralocorticoid receptor antagonist is 
comparable to that of eplerenone, whereas non-dihydropyridine CCBs such as verapamil 
and diltiazem do not have any inhibitory activity.  
8.2 Aldosterone synthase inhibitors 
The other new class of anti-aldosterone agents includes the selective aldosterone-synthase 
inhibitors.  Aldosterone synthase or CYP11B2 is an enzyme of the cytochrome P450 family 
with steroid 18-hydroxylase and 18-oxidase properties. It catalyzes the formation of 
aldosterone from 11-deoxycorticosterone within the zona glomerulosa in the adrenal cortex 
(Figure 3). CYP11B2 deficiency in humans is characterized by a low/absent aldosterone 
synthesis in the adrenal cortex, high plasma renin activity and is responsible for a sodium-
wasting phenotype associated with retarded growth. Conversely, enhanced activation of 
CYP11B2 as it is supposed to occur in the polymorphism 344C/T, is associated with 
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increased left ventricular mass and greater risk to develop hypertension. Since CYP11B2 
activity is the limiting biochemical step in aldosterone synthesis, its selective inhibition is a 
good target for prevention of aldosterone untoward effects mediated by both 
mineralocorticoid receptor-dependent and mineralocorticoid receptor-independent 
pathways. 
At present, only two compounds (both synthesized by Novartis®) with selective CYP11B2 
inhibitory properties have been tested in animal models and, very recently, in the clinical 
setting. FAD286 is the D-enantiomer of the fadrozole, an aromatase inhibitor developed to 
treat advanced breast cancer, that reduces aldosterone levels and increases plasma renin 
activity in rats fed with either low or high sodium diet. In a transgenic rat model of 
secondary hypertension in which the angiotensinogen gene is overexpressed and circulating 
angiotensin II levels are increased, oral administration of FAD286 has reduced mortality by 
4 times. In transgenic rats treated with FAD286, cardiac hypertrophy, albuminuria, and 
histologic evidence of glomerular damage were less frequent than in control animals. 
Despite very minor effects of FAD286 on blood pressure, its effects on organ damage were 
comparable to those of the angiotensin receptor blocker, losartan. 
Following promising preclinical results, the first aldosterone synthase inhibitor, LCI699, was 
tested in two phase-II clinical trials. LCI699 is similar in structure to FAD286 and it has been 
developed for human use. LCI699 was administered to 14 patients affected by primary 
aldosteronism and effects were compared to those of placebo. After 2 weeks of treatment, 
there was a dose-dependent decrease in plasma aldosterone and an increase in 11-
deoxycorticosterone, potassium, and adrenocorticotropin levels. Treatment induced mild 
reduction of 24-h ambulatory systolic blood pressure by (4.1 mm Hg) after 4 weeks. More 
recently, Calhoun et al. have published the first randomized, double-blind, placebo 
controlled phase-II trial with LCI699 that was conducted in 524 patients with essential 
hypertension. In this trial different doses of LCI699 have reduced 24-h ambulatory systolic 
blood pressure, but only the highest dose has reduced also diastolic blood pressure.  
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